Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             52 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models Gumusgoz, Emrah
19 3 p. 982-993
 artikel
2 AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models Gumusgoz, Emrah
19 3 p. 982-993
 artikel
3 A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity Nuber, Silke
19 3 p. 1018-1036
 artikel
4 A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity Nuber, Silke
19 3 p. 1018-1036
 artikel
5 Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair Havla, Joachim
19 3 p. 774-784
 artikel
6 Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair Havla, Joachim
19 3 p. 774-784
 artikel
7 Antibody Therapies in Autoimmune Encephalitis Smets, I.
19 3 p. 823-831
 artikel
8 Antibody Therapies in Autoimmune Encephalitis Smets, I.
19 3 p. 823-831
 artikel
9 Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options Zeng, Rachel
19 3 p. 911-921
 artikel
10 Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options Zeng, Rachel
19 3 p. 911-921
 artikel
11 Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management Vanoli, Fiammetta
19 3 p. 897-910
 artikel
12 Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management Vanoli, Fiammetta
19 3 p. 897-910
 artikel
13 Anti-complement Agents for Autoimmune Neurological Disease McCombe, Jennifer A.
19 3 p. 711-728
 artikel
14 Anti-complement Agents for Autoimmune Neurological Disease McCombe, Jennifer A.
19 3 p. 711-728
 artikel
15 Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies Dalakas, Marinos C.
19 3 p. 741-752
 artikel
16 Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies Dalakas, Marinos C.
19 3 p. 741-752
 artikel
17 Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State Lyu, Jingwei
19 3 p. 994-1006
 artikel
18 Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State Lyu, Jingwei
19 3 p. 994-1006
 artikel
19 CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy Happi Mbakam, Cedric
19 3 p. 931-941
 artikel
20 CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy Happi Mbakam, Cedric
19 3 p. 931-941
 artikel
21 Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics Markowicz-Piasecka, Magdalena
19 3 p. 942-976
 artikel
22 Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics Markowicz-Piasecka, Magdalena
19 3 p. 942-976
 artikel
23 Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases Stathopoulos, Panos
19 3 p. 691-710
 artikel
24 Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases Stathopoulos, Panos
19 3 p. 691-710
 artikel
25 Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome Rajabally, Yusuf A.
19 3 p. 885-896
 artikel
26 Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome Rajabally, Yusuf A.
19 3 p. 885-896
 artikel
27 Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial Zhu, Cheng
19 3 p. 1037-1046
 artikel
28 Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial Zhu, Cheng
19 3 p. 1037-1046
 artikel
29 Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management Krajnc, Nik
19 3 p. 753-773
 artikel
30 Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management Krajnc, Nik
19 3 p. 753-773
 artikel
31 Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD Redenbaugh, Vyanka
19 3 p. 808-822
 artikel
32 Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD Redenbaugh, Vyanka
19 3 p. 808-822
 artikel
33 Neonatal Fc Receptor–Targeted Therapies in Neurology Nelke, Christopher
19 3 p. 729-740
 artikel
34 Neonatal Fc Receptor–Targeted Therapies in Neurology Nelke, Christopher
19 3 p. 729-740
 artikel
35 Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy Terluk, Marcia R.
19 3 p. 1007-1017
 artikel
36 Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy Terluk, Marcia R.
19 3 p. 1007-1017
 artikel
37 Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors Duong, Sophie L.
19 3 p. 848-863
 artikel
38 Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors Duong, Sophie L.
19 3 p. 848-863
 artikel
39 Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies Dalakas, Marinos C.
19 3 p. 832-847
 artikel
40 Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies Dalakas, Marinos C.
19 3 p. 832-847
 artikel
41 The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine Cohen, Fred
19 3 p. 922-930
 artikel
42 The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine Cohen, Fred
19 3 p. 922-930
 artikel
43 Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies Dalakas, Marinos C.
19 3 p. 687-690
 artikel
44 Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies Dalakas, Marinos C.
19 3 p. 687-690
 artikel
45 Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies Briani, Chiara
19 3 p. 874-884
 artikel
46 Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies Briani, Chiara
19 3 p. 874-884
 artikel
47 The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies Querol, Luis A.
19 3 p. 864-873
 artikel
48 The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies Querol, Luis A.
19 3 p. 864-873
 artikel
49 Two Diseases—One Preclinical Treatment Targeting Glycogen Synthesis Gentry, Matthew S.
19 3 p. 977-981
 artikel
50 Two Diseases—One Preclinical Treatment Targeting Glycogen Synthesis Gentry, Matthew S.
19 3 p. 977-981
 artikel
51 What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us? Krämer, Julia
19 3 p. 785-807
 artikel
52 What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us? Krämer, Julia
19 3 p. 785-807
 artikel
                             52 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland